Trial Profile
The Association Between HSD3B1 Genotype and Steroid Metabolism in Normal and Prostate Cancer Tissue of Men With Intermediate and High-risk Prostate Cancer Undergoing Radical Prostatectomy After Treatment With ARN-509 and Leuprolide
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jun 2022
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary) ; Leuprorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics
- 15 Oct 2020 Status changed from recruiting to completed.
- 19 Jul 2020 Planned End Date changed from 1 Oct 2020 to 1 Dec 2020.
- 19 Jul 2020 Planned primary completion date changed from 1 Oct 2020 to 1 Dec 2020.